Revvity, a diagnostics and life sciences company, has recently launched its T-SPOT.TB test for latent TB screening in the country. The announcement was made at MICROCON in Lucknow. Revvity's T-SPOT.TB is the only commercially available IGRA (Interferon-Gamma Release Assay) based on the ELISPOT technology approved by the FDA. This technology involves isolating, washing, and counting peripheral blood mononuclear cells (PBMCs) from whole blood to standardize the test and provide reproducible results. The test is reliable even in challenging-to-screen groups, such as the immunosuppressed.

Shripad Joshi, President, India & South Asia at Revvity, said, "With approximately 40% of the Indian population being infected with latent TB, detecting the infection before it progresses to active disease, which is symptomatic and infectious, is paramount. We recognize the critical role that collaboration between the public and private sectors plays in the Government's mission of eradicating TB by 2025. As a result, we are committed to working closely with the Indian healthcare sector to integrate our reliable, single-visit T-SPOT.TB test into the country's existing healthcare infrastructure, increasing accessibility and affordability of latent TB screening".

Joshi stated that they have collaborated with various healthcare systems worldwide and have 20 years of experience in TB screening. "We are now thrilled to be able to start equipping healthcare professionals in India with advanced screening tools that can support the government's mission effectively, decrease costs associated with treating active or drug-resistant TB, and more importantly, save lives", he added.